康乃德生物 CNTB 深 滬
等待開盤 09-26 09:30:00 美东时间
1.69
-0.030
-1.74%
華盛通- 最 高1.7899
- 今 開1.70
- 成交量 4.09万股
- 最 低 1.64
- 昨 收 1.72
- 總市值 9416.97万
- 52周最高 2.86
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 0.51
- 委 比 82.86%
- 總股本 5572.17万
- 歷史最高 29.274
- 量 比 0.95
- 振 幅 8.72%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Connect Biopharma Executives Increase Share Holdings
Connect Biopharma Holdings ( ($CNTB) ) has issued an announcement. Between Sept...
09-16 21:26
中概股周涨跌榜 | Gamehaus Holdings涨66.7%；房多多涨64.8%；Next Technology跌63.5%，霸王茶姬跌18.3%
Gamehaus Holdings涨66.7%；房多多涨64.8%；Mercurity Fintech涨41.5%
08-30 17:08
天辰生物IPO：递表前一年突击完成三轮融资20亿估值是否虚高？核心药物市场竞争激烈商业化前景待考
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，天辰生物医药（苏州）股份有限公司（以下简称“天辰生物”）递表港交所，拟...
08-29 17:11
麦济生物IPO：8年烧8亿商业化进程仍无时间表 核心产品市场竞争激烈且专利曾陷权属纠纷
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，湖南麦济生物技术股份有限公司（以下简称“麦济生物”）向港交所递交主板上...
08-29 17:08
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Connect Biopharma collaborates with the Jovante Woods Foundation to expand asthma education across the U.S., raising awareness about acute asthma attacks. The partnership marks 15 years since Jovante Woods' death from an asthma attack. The Foundation, established by Ickey and Chandra Woods, focuses on prevention and treatment education. Connect, developing a novel asthma treatment, supports the initiative with a video story and community events d...
08-14 12:00
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
Connect Biopharma GAAP EPS of -$0.23
Connect Biopharma press release (NASDAQ:CNTB): Q2 GAAP EPS of -$0.23. More on Connect Biopharma Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financi...
08-14 00:38
Connect Biopharma Hldgs Q2 EPS $(0.23) Misses $(0.22) Estimate, Sales $48.000K Down From $24.116M YoY
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 185.19 percent decrease over earnings of $0.27 per
08-13 21:14
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma reported significant progress in Q2 2025, advancing its Phase 2 Seabreeze STAT studies for asthma and COPD, showcasing positive data supporting rademikibart’s potential. The company also submitted a new drug application in China via licensee Simcere and terminated its ADR program, listing directly on Nasdaq to enhance institutional visibility. Additionally, Jim Schoeneck, an industry veteran, was appointed to the Board, bringing...
08-13 13:00
中泰证券：创新药企分化加剧 重点推荐先声药业等创新药标杆企业
近期以来，医药板块行情呈现多元化趋势：从创新药单主线驱动，逐步延伸至业绩反转、脑机接口及AI制药等新兴领域，同时创新药内部结构性分化加剧，市场风格呈现高低切...
08-12 10:02
